Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 9, 2003, Pages 4393-4397

  Namba, Hiroyuki ^a,b   Nakashima, Masahiro ^a   Hayashi, Tomayoshi ^a   Hayashida, Naomi ^a   Maeda, Shigeto ^a   Rogounovitch, Tatiana I ^a   Ohtsuru, Akira ^a   Saenko, Vladimir A ^a   Kanematsu, Takashi ^a   Yamashita, Shunichi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN; PROTEIN V599E; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAF GENE; CANCER CELL CULTURE; CANCER STAGING; CELL GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; EXON; FEMALE; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC MARKER; GENETIC STRAIN; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PAPILLARY CARCINOMA; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; THYROID CARCINOMA; TUMOR CLASSIFICATION;

ADULT; CARCINOMA, PAPILLARY; CELL DIVISION; CELL LINE; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; ONCOGENE PROTEINS; PARAFFIN EMBEDDING; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 0141453014     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030305     Document Type: Article

References (22)

1. Farid NR, Shi Y, Zou M 1994 Molecular basis of thyroid cancer. Endocr Rev 15:202-232
2. Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK 1998 Cancer incidence and mortality, 1973-1995: a report card for the U. S. Cancer 82:1197-1207
3. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050-1057; discussion, 1057-1058
4. Nikiforov YE 2002 RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13:3-16
5. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184
6. Suarez HG, du Villard JA, Severino M, Caillou B, Schlumberger M, Tubiana M, Parmentier C, Monier R 1990 Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 5:565-570
7. Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA, Thurston V, Williams ED, Wynford-Thomas D 1988 Activated ras oncogenes in human thyroid cancers. Cancer Res 48:4459-4463
8. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA 2002 Mutations of the BRAF gene in human cancer. Nature 417:949-954
9. Pollock PM, Meltzer PS 2002 A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2:5-7
10. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS 2003 High frequency of BRAF mutations in nevi. Nat Genet 33:19-20
11. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R, Leung SY 2002 Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62:6451-6455
12. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL 2002 BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000
13. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M 2002 Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 62:7001-7003
14. Kurebayashi J, Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M, Sonoo H 2000 All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab 85:2889-2896
15. Hedinger CHR, Williams ED, Sobin LH 1988 WHO international histological classification of tumours; histological typing of thyroid tumors. 2nd ed. Heidelberg: Springer-Verlag
16. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M 2002 ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290
17. Webb CP, Van Aelst L, Wigler MH, Woude GF 1998 Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci USA 95: 8773-8778
18. Namba H, Gutman RA, Matsuo K, Alvarez A, Fagin JA 1990 H-ras protooncogene mutations in human thyroid neoplasms. J Clin Endocrinol Metab 71:223-229
19. Karga H, Lee JK, Vickery Jr AL, Thor A, Gaz RD, Jameson JL 1991 Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab 73:832-836
20. Shirokawa JM, Elisei R, Knauf JA, Hara T, Wang J, Saavedra HI, Fagin JA 2000 Conditional apoptosis induced by oncogenic ras in thyroid cells. Mol Endocrinol 14:1725-1738
21. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR 1995 A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92:7686-7689
22. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR 1999 Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5:810-816